Skip to main content

Table 2 Characteristics of IPD in patients ≥75 years according to PPV23 status, July 2008 to June 2016 (n = 1154)

From: Application of the screening and indirect cohort methods to evaluate the effectiveness of pneumococcal vaccination program in adults 75 years and older in Taiwan

 

Total

%

Unvaccinated

%

Vaccinated

%

p value

Total IPD cases

1154

100

776

100

378

100

 

Total IPD case serotyped

1051

91.1

716

92.3

335

88.6

0.042

Gender

 Female

372

32.2

258

33.2

114

30.2

0.292

 Male

782

67.8

518

66.8

264

69.8

0.292

Onset age

 Median (min~max)

83.1

(75.0~106.6)

82.8

(75.0~106.6)

83.5

(75.1~99.8)

0.002

 75–84

728

63.1

499

64.3

229

60.6

0.219

 85+

426

36.9

277

35.7

149

39.4

0.219

Clinical manifestation

 Sepsis

621

53.8

417

53.7

204

54.0

0.941

 Pneumonia

776

67.2

513

66.1

263

69.6

0.239

 Meningitis

10

0.9

5

0.6

5

1.3

0.311

 Others

1081

93.7

720

92.8

361

95.5

0.108

Death within 30 days of IPD onset

 N

432

37.4

287

37.0

145

38.4

0.651

 Age, Medium (min~max)

83.6

(75.0~100.3)

83.6

(75.0~100.3)

84.1

(75.1~98.2)

0.330

Days between onset to notification

 Median (min~max)

5

(0.0~64.0)

5

(0.0~64.0)

5

(0~40.0)

0.710

Onset season

 2008–2009

166

14.4

130

16.8

36

9.5

0.001

 2009–2010

138

12.0

100

12.9

38

10.1

0.164

 2010–2011

151

13.1

107

13.8

44

11.6

0.310

 2011–2012

162

14.0

107

13.8

55

14.6

0.727

 2012–2013

147

12.7

101

13.0

46

12.2

0.686

 2013–2014

125

10.8

81

10.4

44

11.6

0.538

 2014–2015

147

12.7

83

10.7

64

16.9

0.003

 2015–2016

118

10.2

67

8.6

51

13.5

0.011

Total IPD cases

1154

100

776

100

378

100

 

High risk medical conditions (HRMC)

 With HRMC

591

51.2

378

48.7

213

56.3

0.019

 Immunodeficiency/cancer

240

20.8

152

19.6

88

23.3

0.147

 COPD

214

18.5

133

17.1

81

21.4

0.079

 Congenital heart disease

6

0.5

3

0.4

3

0.8

0.400

 Splectomy/Asplenism

2

0.2

1

0.1

1

0.3

0.548

 Others

189

16.4

125

16.1

64

16.9

0.723

Serotypes

 PCV13 VT

795

68.9

554

71.4

241

63.8

0.009

 PPV23 VT

847

73.4

598

77.1

249

65.9

<.0001

 PPV23-non PCV13 VT

83

7.2

69

8.9

14

3.7

0.001

  1. IPD invasive pneumococcal disease, COPD chronic obstructive pulmonary diseases, VT vaccine type, PCV13 thirteen-valent pneumococcal conjugate vaccine, PPV23 23-valent pneumococcal polysaccharide vaccine, PPV23-non PCV13 VT 11 serotypes that included in PPV23 but not in PCV13, that is serotypes of 2, 8, 9 N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F